The hormonal therapies that our BC patients were on in this study were selective estrogen receptor modulators (SERMs; i.e. Nolvadex) and aromatase inhibitors (i.e., Arimidex, Aromasin, and Femara). This evidence concerns the gene CYP19A1 and breast cancer.